Immune checkpoint blockade for cancer therapy: current progress and perspectives  

作　　者：Hongying YE Wejie LIAO Jiongli PAN Yin SHI Qingqing WANG 

机构地区：[1]Institute of Immunology,Zhejiang University School of Medicine,Hangzhou 310058,China [2]The Key Laboratory for Immunity and Inflammatory Diseases of Zhejiang Province,Hangzhou 310058,China [3]Department of Biochemistry,Zhejiang University School of Medicine,Hangzhou 310058,China

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2025年第3期203-226,共24页浙江大学学报(英文版)B辑(生物医学与生物技术)

基　　金：supported by the National Key Research and Development Program of China(No.2022YFE0102100);the National Natural Science Foundation of China(Nos.U22A20307 and 81930041)。

摘　　要：Dysfunction of anti-tumor immune responses is crucial for cancer progression. Immune checkpoint blockade(ICB), which can potentiate T cell responses, is an effective strategy for the normalization of host anti-tumor immunity. In recent years, immune checkpoints, expressed on both tumor cells and immune cells, have been identified;some of them have exhibited potential druggability and have been approved by the US Food and Drug Administration(FDA) for clinical treatment. However, limited responses and immune-related adverse events(ir AEs) cannot be ignored. This review outlines the development and applications of ICBs, potential strategies for overcoming resistance, and future directions for ICB-based cancer immunotherapy.

关 键 词：Immune checkpoint blockade Cancer immunotherapy Tumor immune evasion Immune normalization 

分 类 号：R730.51[医药卫生—肿瘤]